financetom
Business
financetom
/
Business
/
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing
Nov 25, 2025 2:44 PM

05:27 PM EST, 11/25/2025 (MT Newswires) -- Serge Saxonov, Director, Chief Executive Officer, on November 24, 2025, sold 13,261 shares in 10x Genomics ( TXG ) for $251,936. Following the Form 4 filing with the SEC, Saxonov has control over a total of 1,292,833 Class A common shares of the company, with 1,021,556 shares held directly and 271,277 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1770787/000161071725000398/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zapp Electric Vehicles Signs Distribution Contract in India
Zapp Electric Vehicles Signs Distribution Contract in India
Jun 14, 2024
05:00 AM EDT, 06/14/2024 (MT Newswires) -- Zapp Electric Vehicles Group ( ZAPP ) said it intends to appoint Bounce Electric 1 Private Limited as its contract manufacturing partner for the sales of the i300 in India. The British electric vehicle brand signed a memorandum of understanding to this effect. It said on Thursday Bounce operates a domestic vehicle assembly...
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Jun 14, 2024
05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was well-tolerated and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder. The company describes the drug, also called reni-cel, as...
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Jun 14, 2024
05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease, about 92% of evaluable patients were shown to be free from vaso-occlusive crises, or VOCs, for at least 12 months, while 97% of patients with...
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Jun 14, 2024
05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system. The company said the data showed no serious adverse events, cytokine...
Copyright 2023-2026 - www.financetom.com All Rights Reserved